Management & Governance

Pakorn Nilprapunt, Deputy Prime Minister in charge of legal affairs, disclosed progress on the early retirement programme for ordinary civil servants, saying that relevant agencies are now preparing the details before submitting them to the Cabinet. Only one point remains to be settled: the compensation multiple, which is intended to exceed 12 times salary, and this must be discussed with the Ministry of Finance to finalise the criteria. The initial eligibility group will start at age 50 and above, but those aged 40 and over who wish to join must have necessary reasons, such as resigning to care for parents or health problems, with the head of each agency deciding on a case-by-case basis. The measure is expected to be implemented within fiscal year 2570, targeting a 5% annual reduction in the workforce out of the total number of civil servants. The first phase aims for 5% and will use a budget of 7 billion baht, initially possibly drawn from the central budget, after which the programme budget will gradually decline in subsequent years. As for the reduction of overlapping regional government agencies, Pakorn said the Office of the Public Sector Development Commission is considering the matter and it must be carried out gradually because of the impact on staffing and missions, but he confirmed it will proceed and forms part of a long-term plan.

Haisco announced that the first meeting of the company's sixth board of directors elected Wang Junmin as chairman. The meeting also appointed Yan Pangke as general manager, Wang Meng as deputy general manager and board secretary, Duan Peng as chief financial officer, and Guo Yan as securities affairs representative.

The share reduction plan of Dongcai Technology Chairman Tang Anbin has expired, with a total of 144 million yuan cashed out over three months. According to Dongcai Technology's disclosure, from June 30 to September 29, Tang Anbin reduced his holdings by a cumulative 2.89 million shares through centralized bidding, accounting for 0.29% of the company's total share capital, at prices ranging from 48.56 yuan to 54.31 yuan per share, for a total reduction amount of 144 million yuan. This reduction stemmed from a plan announced in June this year, when Tang Anbin, due to personal funding needs, intended to reduce his holdings by no more than 2.9012 million shares within three months starting June 30, representing 0.29% of total share capital, and ultimately reduced 2.89 million shares. Before the reduction, Tang Anbin held 11.6051 million shares, or 1.15%; after completion, his holdings fell to 8.7151 million shares, with his stake dropping to 0.86%. Born in 1968, Tang Anbin has served as chairman since December 2019, and his pre-tax compensation from the company in 2025 was 2.4613 million yuan. This is not his first reduction; including this one, Tang Anbin's cumulative reduction totals approximately 21.04 million shares, cashing out about 356 million yuan. In addition, several directors and senior executives, including director and general manager Li Gang, have also completed reductions this year. Dongcai Technology focuses on new chemical materials such as optical film materials and electronic materials. In the first half of this year, it achieved operating revenue of 3.095 billion yuan, up 27.29% year-on-year, and net profit attributable to the parent of 312 million yuan, up 63.78% year-on-year.

Federal Home Loan Mortgage has named John Glessner as its new Chief Risk Officer, effective October 1, 2026, succeeding longtime risk chief Anil Hinduja, who has departed. Glessner previously led investments and capital markets at the company. The leadership change comes amid a sharp selloff in the shares, which are down 7.3% over the past week, almost 30% over 30 days, and 64.44% year to date, though the three-year total shareholder return remains near 5x. A widely followed narrative values the stock at a fair value of $14.70 against a last close of $3.68, implying it is 75% undervalued, supported by mission-driven affordable housing exposure, including the majority of financed units affordable to households at or below 120% of area median income and 66% of multifamily new business labeled mission driven affordable. That narrative could break if refinancing stays muted in a higher rate backdrop or if housing policy shifts hit affordable volumes.

Sweco AB announced on 2 October 2026 that long-serving CEO and President Åsa Bergman will resign after 35 years at the company, remaining in her role until a successor is appointed. Her departure ends a nearly nine-year leadership tenure at Europe's largest architect and technology consulting firm, raising questions about future leadership direction. The company's Q2 and H1 2026 results showed higher sales and earnings versus the prior year, underpinning an investment story built on operational efficiency and a strong pipeline in rail, hospitals and grid projects. Sweco's narrative projects SEK39.0 billion revenue and SEK3.4 billion earnings by 2029, requiring 6.2% yearly revenue growth and about SEK1.1 billion earnings increase from SEK2.3 billion today, while some of the lowest analysts assumed revenue of about SEK38,100,000,000 and earnings of SEK3,200,000,000 by 2029. Bergman's resignation puts extra focus on whether the incoming CEO will sustain that margin focus and project discipline while managing softer real estate and Finnish demand and ongoing restructuring costs.

Origin Bancorp disclosed that Dr. Richard Gallot, Jr. has resigned from its Board of Directors, a change the company recorded in a recent filing. The departure trims one voice from the boardroom and reduces the current roster of directors, adjusting the mix of experience guiding the regional lender. Origin Bancorp runs Origin Bank, which serves small and medium-sized businesses, municipalities, and retail customers across Texas, Louisiana, Alabama, and Mississippi. The resignation does not directly alter the balance sheet, but it slightly shifts the oversight mix behind the company's Optimize Origin program, capital returns, and disciplined credit and funding decisions. Investors will watch how the board fills the vacancy and whether any refresh is tied to skills such as data centric banking, Southern market expertise, or fee income growth, with the next proxy statement and future board or committee disclosures as the key markers.

Wendel has appointed Bénédicte Rabier as Chief Product Officer for Wendel Investment Managers, a move aimed at sharpening its third party asset management offering. The appointment comes as the shares trade around €79.35, with a 1-day share price return of 1.34% and a 7-day gain of 2.65%, though the 30-day share price return is down 6.87%. Over longer horizons, Wendel's 1-year total shareholder return stands at 2.95% and its 3-year total shareholder return at 26.71%, against a 5-year total shareholder return that is down 15.31%. The most followed narrative sets a fair value of €106.67, framing the current price as 26% undervalued, while the SWS DCF model estimates a value of €61.20 and flags the shares as overvalued. Concentration in non listed holdings and exposure to unhedged US dollar assets are cited as risks to the undervaluation case.

The Estée Lauder Companies appointed Gaétane Baudry as Senior Vice President and Global General Manager of Bobbi Brown in early October 2026, tasking her with leading the brand's global strategy, innovation agenda and consumer engagement from New York. Baudry brings luxury beauty experience across Shu Uemura, Giorgio Armani Beauty, Helena Rubinstein and Lancôme, giving Estée Lauder an experienced operator to refine Bobbi Brown's positioning and execution as the group emphasizes product innovation and brand-led growth. The appointment sharpens execution in a core makeup brand but does not materially change the near-term catalyst of margin follow-through under the Profit Recovery and Growth Plan and the One ELC model, nor the main risk of restructuring disrupting consumer-facing operations. Estée Lauder's narrative projects $17.1 billion revenue and $1.5 billion earnings by 2029, requiring 4.4% yearly revenue growth and about a $1.3 billion earnings increase from $182.0 million today, with a $107.04 fair value implying 9% upside. Some of the lowest ranked analysts assume revenue of about US$16.9 billion and earnings of roughly US$1.5 billion by 2029, viewing execution and cash conversion risks differently from those who see Baudry's appointment as reinforcing the existing recovery story.

Goodyear Tire & Rubber controller Margaret V. Snyder has resigned effective October 16, 2026, with veteran finance executive Stephen F. Shamrock stepping in as controller and principal accounting officer under the company's existing succession plan. The leadership change comes as Goodyear shares trade at US$4.68, down 18.61% over the past month and 31.28% over 90 days, with a 1-year total shareholder return of negative 31.48% and a 5-year total shareholder return of negative 75.16%. The leading narrative on the stock points to a fair value of $10.50, framing it as 55% undervalued against the last close. That repair story leans heavily on improving Americas profitability and managing roughly US$6.3b of net funded debt without further strain.

Goodyear Tire & Rubber elected Joe Hinrichs as chairman of its Board of Directors, replacing Laurette Koellner. Hinrichs previously served as CEO of CSX Corporation and held senior executive roles at Ford Motor Company, bringing operating experience from complex industrial groups to a tire maker with a market cap of about $1.4 billion. The boardroom shift comes as Goodyear pursues cost cuts, a tilt toward premium tires and a cleaner balance sheet under its Goodyear Forward program, set against pressure from low cost rivals, tariffs and weak commercial volumes. Investors will watch whether the new chair translates boardroom priorities into financial traction after the Q1 2026 loss of about US$249 million and Q2 2026 loss of US$204 million, with updates expected through 2027 on Goodyear Forward cost savings, progress on the Fayetteville closure and tire volume trends by region and segment.

Northern Trust announced that long-serving Chief Financial Officer Dave W. Fox, Jr. plans to retire around March 31, 2027, with a formal internal and external search now underway. The succession process is mapped out years in advance, pairing with a recent pullback in the shares: Northern Trust's 1 month share price return is down 8.9% and its 3 month share price return is lower by 8.4%, while the year to date share price return of 20.8% and 1 year total shareholder return of 37.7% point to longer-term momentum. The most followed valuation story pegs fair value at $184.27, above the last close at $168.21, framing the pullback as a discount that hinges on execution, with technology and AI programs, including AI assisted code development and a plan for tech spend growth to moderate toward mid single digit rates, supporting a multi year effort to raise productivity and expand margins. A simple P/E check tells a more mixed story: at 14.1x earnings the shares trade above a fair ratio of 12.8x, though far below the US Capital Markets average of 39.3x and a 22.8x peer group. The story could be knocked off course if adviser poaching pushes compensation higher or if liquidity products face sharper fee pressure.

Jingxin Pharmaceutical has recently updated its H-share listing application with the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. This marks the company's second submission of listing materials to the main board of the Hong Kong Stock Exchange, following the lapse of its first filing in February 2026 after the six-month validity period expired. The Hong Kong fundraising is earmarked for four main purposes: new drug research and development, market channel expansion, industrial mergers and acquisitions and cooperation, and general working capital. However, the company has not disclosed the specific proportion of investment for each direction, nor has it disclosed details of the corresponding research and development pipeline. Financial data shows that as of the end of 2025, the company's cash-like assets totaled as much as 2.385 billion yuan, while interest-bearing liabilities in the same period were only 215 million yuan in short-term borrowings, with no long-term debt pressure. From 2023 to 2025, operating cash flow amounted to 793 million yuan, 726 million yuan, and 781 million yuan respectively. In 2025, the company implemented cash dividends of 287 million yuan and share repurchases of 609 million yuan, with the combined amount of dividends and repurchases accounting for 118.21 percent of the net profit attributable to the parent company for that year. At the same time, the company's research and development expenses have declined for three consecutive years, falling from 401 million yuan to 383 million yuan, and further dropping to 368 million yuan. The proportion of research and development investment to revenue also decreased from 10.0 percent to 9.0 percent. In the first half of 2026, research and development expenses fell 10.89 percent year-on-year, with the revenue share further declining to 8.3 percent. Revenue for the period was 1.987 billion yuan, down 1.46 percent year-on-year, and net profit attributable to the parent company was 352 million yuan, down 9.35 percent year-on-year. The prospectus discloses that the utilization rate of the company's core generic drug production lines fell from 77 percent in 2023 to 61.3 percent in the first half of 2026, while the utilization rate of traditional Chinese medicine production lines dropped from 55.6 percent to 24.9 percent. As the core asset of the company's transformation and innovation, the only approved Class 1 innovative drug, Dimdazenil, under the trade name Jingnuoning, was approved for marketing in November 2023 and included in the national medical insurance catalog in November 2024. However, this product was not independently developed but is a licensed-in variety. Jingxin Pharmaceutical obtained the development and commercialization rights in China through a licensing agreement in 2010. The fastest-progressing candidate in the research pipeline is JX2201, targeting the Lp(a) cardiovascular target, which has obtained an Investigational New Drug approval in the United States but has not yet initiated overseas clinical trials. The Phase I clinical trial in China has been completed, and Phase II dose exploration studies are currently being advanced.

Guoguang Electric announced on the evening of October 9 that board secretary Wang Shangbo has resigned for personal reasons. After his resignation, he will no longer hold any other position at the company, and the resignation takes effect from the date the report is delivered to the board of directors. Until a new board secretary is appointed, Chairman Zhang Ya will perform the duties of board secretary. Wang Shangbo was born in February 1991. His previous career was entirely in the public fund industry, with stints at Lion Fund and Baoying Fund, and he also served as a separately managed account investment manager and public fund manager at Shenzhen Capital Group's Laterite Innovation Fund. From January to September 2024, he was head of investment at Chengdu Screen Microelectronics, and in September 2024 he became board secretary of Guoguang Electric, making him the youngest of the company's 16 directors, supervisors, and senior executives at the time. As of the disclosure date of the announcement, Wang Shangbo holds 36,100 shares in Guoguang Electric.

ST Kaili announced on the evening of October 9 that the company held the 22nd meeting of its sixth board of directors by telecommunication on October 7, and approved the proposal to change the company's chairman by a vote of 4 in favor and 3 against, appointing Hui Yiwei as chairman. Former chairman Wang Chong remains a director. The proposal was put forward by shareholders holding more than one-tenth of voting rights combined, including Shanghai Kaicheng Juntai Investment Co., Ltd., Lü Xiangdong, Li Hong, Liu Shuangquan, and Wei Yongmei, and was passed by the board. The announcement said the change was based on a major shift in the company's shareholding structure, aiming to improve corporate governance, enhance decision-making efficiency, and promptly eliminate circumstances that triggered the other risk warning. Directors Wang Chong, WEN CHEN, and independent director Zhu Dingmin voted against, citing concerns over Hui Yiwei's independence, competence, management experience, and the stability of the current governance structure. ST Kaili has long had a fragmented shareholding structure with no actual controller, and its largest shareholder, Yongjin Investment Holding Co., Ltd., holds only 7 percent.

Jianxin Chemical announced that company general manager and board secretary Chen Xuewei has resigned from the board secretary role due to internal work adjustments, while continuing to serve as general manager. As of the announcement disclosure date, he holds 6,847,219 shares of the company, accounting for 1.22% of total share capital. This is the second time Chen Xuewei has stepped down from the role. He had served concurrently as board secretary for nearly seven and a half years starting in December 2007, stepped down in May 2015, and was reappointed in August 2022, serving until his recent departure. On October 9, 2026, at the fourth meeting of the company's seventh board of directors, following nomination by the chairman and qualification review by the nomination committee, the board approved the appointment of Gao Song as board secretary, with a term from the date of board approval until the end of the seventh board's term. Gao Song was born in 1984. He holds a bachelor's degree in automotive engineering from Tsinghua University and a master's degree in mechanical engineering from the Technical University of Munich in Germany. From October 2007 to September 2009, he served as assistant manager for Asia-Pacific procurement in the global purchasing department of BMW. From September 2009 to June 2018, he worked at CITIC Securities, serving successively as senior analyst for the automotive industry and chief analyst for the defense industry. Since December 2018, he has served as assistant to the chairman of Jianxin Chemical. Gao Song is the son-in-law of Zhu Shouchen, the company's controlling shareholder and actual controller, and the husband of company director Zhu Zerui.

The White House said on the 9th that President Trump has established an investigative committee over allegations of mortgage fraud by Federal Reserve Board Governor Cook. The Supreme Court ruled in June of this year not to allow Cook's immediate removal, but Trump continues to seek her dismissal. The independence of the Federal Reserve could once again be significantly shaken.

Cisco has appointed Girish Rishi to its board of directors, effective October 9, 2026. Rishi is Chairman and Chief Executive Officer of Cognite, an industrial AI company, and a Senior Advisor to Blackstone. He brings three decades of technology leadership across hardware, software and systems, including prior roles as CEO of Blue Yonder and executive positions at Tyco International, Zebra Technologies, Motorola Solutions and Symbol Technologies. Cisco Chair and CEO Chuck Robbins said Rishi's expertise in data and AI will be invaluable as Cisco provides the critical infrastructure organizations need to lead in the AI era. Rishi also serves on the board of Insight Enterprises and is a member of the Council on Foreign Relations and an executive board member of the Arizona Commerce Authority.

Lululemon Athletica has reset its leadership lineup, creating new President & Chief Product Officer and Chief Operating Officer roles while starting searches for three more senior hires. The shares last closed at US$92.68 after a 1-day share price return of 0.87%, and remain down 10.19% over 30 days, 22.29% over 90 days, with a 1-year total shareholder return of negative 46.58%. The most followed narrative values the company at $139 per share, a 33% undervalued call, while a discounted cash flow model lands closer to $83.98, framing the current price as expensive. That narrative holds that lululemon still earns high returns on capital and retains a direct-to-consumer structure that supports margins, even as earnings pressure, tariffs and weaker Americas demand weigh on reported results, and it acknowledges the brand reset has been more painful than expected. The reset story could break if earnings pressure deepens or if the leadership changes fail to steady falling shareholder returns.

Vertiv Holdings Co has appointed Michael Resha as Executive Vice President of Manufacturing, Logistics and Operational Excellence, with former EVP Anders Karlborg moving into a transition-focused Special Operations Projects role. The leadership reshuffle comes as Vertiv shares have slipped around 16% over the past month and roughly 24% over the last quarter, though the year to date share price return remains about 39% and the 5 year total shareholder return is close to a 10x gain. The stock last traded at US$243.73, and the most followed community narrative pegs fair value at $450, framing the shares as 46% undervalued. Vertiv's current P/E sits at 54.2x against a fair ratio of 50.6x, an Electrical industry average of 35.7x and a peer average of 38.4x. The company's story could still crack if large AI data center projects are delayed or if rivals undercut liquid cooling economics and pressure already debated valuation multiples.

AB Science reported an operating loss of €10.4 million for the first half of 2026, compared with a loss of €2.7 million a year earlier, and announced the appointment of Stéphane Ledermann as Chairman and Chief Executive Officer. The wider loss was mainly due to a €6.5 million provision tied to the Research Tax Credit dispute with French tax authorities, following an unfavourable Paris Administrative Court ruling on 22 September 2026; net income came to -€9.0 million versus -€5.2 million in the first half of 2025. Revenue, consisting solely of veterinary drug Masivet sales, was €498 thousand, down slightly from €515 thousand, while cash and cash equivalents stood at €8.9 million as of 30 June 2026, supplemented by €16.5 million raised through private placements in July and August 2026. The company also obtained clinical trial insurance for its Phase 3 amyotrophic lateral sclerosis study with a liability limit of €25 million that can be increased to €39 million, and reported a 67% overall response rate in Stage 3 of the Phase 1 AB8939 plus Venetoclax study in relapsed or refractory acute myeloid leukaemia. AB Science said it expects to resume the Phase 1 acute myeloid leukaemia study in the first quarter of 2027 and the Phase 3 ALS study in the fourth quarter of 2027, and will hold a web conference on 14 October 2026 to present its new roadmap.

Stryker Corporation said on October 6 that Kevin Lobo will become executive chairman and Spencer Stiles will become chief executive, both effective January 1. The succession comes with the shares at around $275 on October 7, down 1.01% on the day and 24.85% lower over twelve months, and 30% below their 52-week high of $392.55. The handover is not a response to the operating numbers: revenue grew 9.40% in the most recent quarter, earnings grew 44.30%, and free cash flow of $4.70 billion exceeded $3.73 billion of net income. The stock trades at 28.84 times trailing earnings and 16.49 times forward, a gap that shows the market expects earnings to rise sharply but will not pay for the increase in advance. Spencer Stiles inherits that gap on January 1, and the number to watch is operating margin, because 27.02% is what the new chief executive has to defend first.

President Donald Trump has revived his campaign to oust Lisa Cook from the Federal Reserve's board of governors, issuing a memo ordering the formation of a committee on inquiry to investigate allegations that Cook made false statements on one or more mortgage loan applications. The memo is dated Oct. 7, 2026, but only appeared on the White House's website on Friday, and it sets an in-person hearing to consider evidence and allegations on Nov. 5, 2026. In the memorandum, Trump wrote that the committee shall investigate the allegations against Governor Cook and report to him whether there is cause for her removal, and the committee may consult personnel from executive departments and agencies, including the Department of Justice. Cook may submit a written position statement to the committee, which must be received at least three days before the hearing. Trump originally tried to fire Cook in August 2025 without an inquiry or investigation, and Cook has sued the president, saying he lacks the authority to remove a Fed governor and did not provide due process; in July, the Supreme Court allowed Cook to stay on the Fed board while her suit proceeds. The president has been frustrated by the monetary policymakers' refusal to cut interest rates, and the Federal Open Market Committee raised its benchmark rate by 25 basis points to 3.75%-4.00% last month.